



Presentation for GGD Amsterdam, October 2020

Strictly Confidential



Agenda


- AeoNose exhaled-breath analysis
 - Features
 - Status
- Pilot results for Covid-19
- Proposed approach for GGD Amsterdam
- Discussion items
- Next steps



Features AeoNose

- Point-of-Care device
 - 5 minutes breathing, 10 minutes rinsing, immediate classification
 - Portable, battery-powered
 - CE, ISO 13485
- Non-invasive
- Disposable mouth piece & filters
- iPad controlled: communicating with data center







Point-of-Care exhaled-breath analysis



Status AeoNose

- 20 years of know-how in eNose technology, 10 years in medical applications,
- Solid approach
- > 90 papers & conference contributions on various indications,
- Finishing-up multi-center validation studies on lung cancer and colorectal cancer,
- Pilot study on Covid-19
 - 50 devices in stock
 - Production (outsourced), CE, ISO 13485









Pilot study results for Covid-19

- Clinical study at MUMC
- 219 participants (MUMC employees)







Proposed approach for GGD Amsterdam

- Setting-up task force (if not available already)
 - Epidemiologist
 - Virologist / microbiologist
 - •
 - Academic back-up
- Protocol
 - 'Golden' standard
 - Sample size
 - Follow-up participants
 - Preferably: approval by METC
- Building algorithm
 - Collecting breath samples
 - Data analysis
 - Check with blind samples (validation)



Proposed approach for GGD Amsterdam

- Timeframe
 - Protocol + METC 1 week
 - Breath sampling & building algorithm 4 weeks
- Dedicated training and support available from The eNose Company





Discussion items

- Sensitivity & specificity required (sensitivity swab-PCR ± 75%)
- Approval by authorities ?
- Numbers of devices & consumables needed
- Costs involved





Next steps

• How do we proceed from here?

